Abstract: A test fixture couples with a test instrument to measure impedance of a device. An upper layer of the test fixture has (a) a first and a second solder pad for electrical connection to the device, (b) a first, second, third and fourth multi-solder pad for electrical connection to four connectors, (c) a first conductor track for connecting the first solder pad to a signal solder pad of the first multi-solder pad, (d) a second conductor track for connecting the first solder pad to a signal solder pad of the second multi-solder pad, (e) a third conductor track for connecting the second solder pad to a signal solder pad of the third multi-solder pad, and (f) a fourth conductor track for connecting the second solder pad to a signal solder pad of the fourth multi-solder pad. Each multi-solder pad has at least one return path solder pad. A lower layer of the test fixture has conductor tracks connected to the return path solder pad of each multi-solder pad.
Type:
Grant
Filed:
December 20, 2005
Date of Patent:
April 29, 2008
Assignee:
The Trustees of Dartmouth College
Inventors:
Charles Roger Sullivan, Satish Prabhakaran
Abstract: The present invention relates to a method of detecting intracellular cholesterol. The method provides contacting a permeabilized cell with labeled c? complex. Methods of using this detection method to identify agents which modulate cholesterol accumulation in a cell are also provided.
Abstract: A novel sarR gene and sarR gene product which down regulates the expression of sarA and the resulting virulence determinants in Staphylococcus aureus is provided. Methods for modulating the expression of sarA and virulence determinants are also provided. A preferred embodiment of the present invention provides structural information relating to the gene product and enables the identification and formulation of lead compounds and reducements for treating and preventing infections by S. aureus and related bacteria.
Abstract: Recombinant plasminogen activator inhibitor-1 (PAI-1) isoforms which lack the reactive center loop and contain the complete heparin-binding domain or lack at least a portion of the heparin-binding domain are described. The rPAI-1 isoforms disclosed herein may be used to modulate angiogenesis through blocking release of VEGF from a VEGF-heparin complex. Furthermore, the rPAI-1 proteins may be used to inhibit cell proliferation and migration, induce apoptosis, and produce proteolytic fragments corresponding to angiostatin kringles 1-3 and kringles 1-4. A truncated proteolytic plasmin protein of 34 kDa is also provided.
Abstract: The invention provides a method for encrypting a program for execution on a remote host computer on a network, such that correct execution by the remote host computer is ensured, and such that the remote host computer remains unaware of the computations or data associated with execution. Results from the computations at the remote host computer are transmitted to a control computer, on the network, which decodes the results to useful data representative as output from the program. In a first step of the method, the program is encoded as a unitary matrix multiplication, Uij, of i dimensions by j dimensions. Un is the set of unitary matrices of size n, forms a non-commutative group under matrix multiplication, and has a unique group-invariant Haar measure probability distribution; Uij is thus an element of Un. In a second step, an input data string to the program is encoded as a vector bj of n dimensions. The first and second steps can be performed in either order.
Abstract: Compounds and methods useful for chemopreventative treatment of diseases such as cancer, Alzheimer's disease, Parkinson's disease, inflammatory bowel diseases, and multiple sclerosis.
Type:
Grant
Filed:
March 24, 2003
Date of Patent:
October 30, 2007
Assignee:
Trustees of Dartmouth College
Inventors:
Gordon W. Gribble, Tadashi Honda, Michael B. Sporn, Nanjoo Suh
Abstract: The present invention relates to methods of treating pain. Monocyte chemoattractant protein-1 (MCP-1) antibodies or binding fragments thereof are used to prevent or reduce behavioral hypersensitivity associated with pain.
Abstract: The infection of a mammalian host by a microorganism can be prevented or treated through the alteration of the C. albicans homologue of the high affinity phosphodiesterase, PDE2, gene and/or the adenylate cyclase-associated protein gene. These methods may be used in the identification, prevention or treatment of microbial infection of mammalian hosts such as immunocompromised or immunosuppressed humans, for example, those having AIDS or undergoing transplantation or anti-cancer therapy.
Abstract: A novel sarR gene and sarR gene product which down regulates the expression of sarA and the resulting virulence determinants in Staphylococcus aureus is provided. Methods for modulating the expression of sarA and virulence determinants are also provided. A preferred embodiment of the present invention provides structural information relating to the gene product and enables the identification and formulation of lead compounds and reducements for treating and preventing infections by S. aureus and related bacteria.
Type:
Grant
Filed:
January 11, 2002
Date of Patent:
August 21, 2007
Assignee:
Trustees of Dartmouth College
Inventors:
Ambrose L. Cheung, Adhar Manna, Gongyi Zhang
Abstract: A nucleic acid sequence which regulates the autolytic activity of bacteria is provided. Methods for identifying and using agents which interact with the gene to inhibit bacterial growth and infectivity also are provided.
Abstract: Recombinant plasminogen activator inhibitor-1 (PAI-1) isoforms which lack the reactive center loop and contain the complete heparin-binding domain or lack at least a portion of the heparin-binding domain are described. The rPAI-1 isoforms disclosed herein may be used to modulate angiogenesis through blocking release of VEGF from a VEGF-heparin complex. Furthermore the rPAI-1 proteins may be used to inhibit cell proliferation and migration, induce apoptosis, and produce proteolytic fragments corresponding to angiostatin kringles 1–3 and kringles 1–4.
Type:
Grant
Filed:
April 1, 2003
Date of Patent:
July 10, 2007
Assignee:
Trustees of Dartmouth College
Inventors:
Mary Jo Mulligan-Kehoe, Richard J. Powell
Abstract: Compositions and methods for regulating CD154 gene expression are provided that rely on the interaction of polypyrimidine tract proteins with the 3?-untranslated region of CD154.
Abstract: A first electrode is separated from a second electrode by an interelectrode space. The interelectrode space does not exceed 3 mm, and preferably does not exceed 100 ?m. Liquid water fills the interelectrode space, thereby electrically connecting the first electrode and the second electrode. A power supply, preferably low-frequency AC, is connected to the first and second electrodes, generating a current through the water in the interelectrode space. The applied electric power prevents freezing of a thin liquid water layer in the interelectrode space, thereby preventing ice formation.
Abstract: The present invention provides applicators for performing thermokeratoplasty. One embodiment of such applicators includes two generally tubular electrical conducting elements coaxially disposed relative to one another and separated by an electrically insulating element having a selected thickness. At least a portion of each conducting tube is coated with an electrically insulating and thermally conductive material, e.g., anodized aluminum, so as to electrically insulate the conducting tubes from corneal tissue upon placement of the applicator on a subject's cornea while facilitating extraction of heat from the cornea.
Abstract: Novel molecules of the multi-drug and toxin efflux (MATE) family of molecules, designated herein as mutant ferric reductase defective (FRD3) nucleic acid and protein molecules are disclosed. The FRD3 nucleic acid and protein molecules are useful as modulating agents in regulating metal homeostasis, e.g., iron homeostasis. The invention further describes transgenic plants in which expression of a FRD3 polypeptide of the invention is altered. Compositions containing FRD3 molecules and methods of using such molecules are also provided.
Abstract: The present invention relates to a method of detecting intracellular cholesterol. The method provides contacting a permeabilized cell with labeled C? complex. Methods of using this detection method to identify agents which modulate cholesterol accumulation in a cell are also provided.
Abstract: Novel tricyclic-bis-enone derivatives (TBEs) as well as the process for the preparation of such TBEs are provided. Also provided are methods for prevention and/or treatment of cancer, Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotropic lateral sclerosis, rheumatoid arthritis, inflammatory bowel disease, and all other diseases whose pathogenesis is believed to involve excessive production of either nitric oxide (NO) or prostaglandins or the overexpression of iNOS or COX-2 genes or gene products. Further, methods for the synthesis of the TBE compounds of the invention utilize cheap commercially available reagents and are highly cost effective and amenable to scale-up. Additional high efficiency synthetic methods that utilize novel intermediates as well as the synthesis of these intermediates are also provided. Furthermore, the invention also provides methods for designing novel and water-soluble TBEs.
Type:
Grant
Filed:
January 15, 2003
Date of Patent:
February 13, 2007
Assignee:
The Trustees of Dartmouth College
Inventors:
Tadashi Honda, Frank G. Favaloro, Gordon W. Gribble, Michael B. Sporn, Nanjoo Suh
Abstract: An animal selected for lacking heparan sulfate 3-O-sulfotransferase-1 activity is provided. This animal exhibits characteristics associated with myxomatous valvular disease and is useful for identifying agents which prevent, delay or treat myxomatous valvular disease. Methods of diagnosing myxomatous valvular disease are also provided.
Type:
Grant
Filed:
February 10, 2003
Date of Patent:
January 23, 2007
Assignees:
Trustees of Dartmouth College, Massachusetts Institute of Technology (MIT)
Inventors:
Nicholas W. Shworak, Robert D. Rosenberg, Robert T. Palac
Abstract: High-frequency AC voltage with a frequency in a range of from 60 to 100 kHz supplied from a power source at 3 to 15 kV is applied to an electrical conductor within about 30 cm of a cableway. The high-frequency AC voltage generates an alternating electric field. Capacitive AC current associated with the alternating electric field flows through the ice on the cableway and on the electrical conductor, causing dielectric loss heat that melts the ice.
Type:
Grant
Filed:
January 24, 2002
Date of Patent:
January 16, 2007
Assignee:
The Trustees of Dartmouth College
Inventors:
Victor F. Petrenko, Charles R. Sullivan